Towards a Vaccine Against Rheumatic Fever
Open Access
- 1 January 2000
- journal article
- review article
- Published by Wiley in Clinical and Developmental Immunology
- Vol. 13 (2-4), 125-132
- https://doi.org/10.1080/17402520600877026
Abstract
Rheumatic fever (RF) is an autoimmune disease which affects more than 20 million children in developing countries. It is triggered by Streptococcus pyogenes throat infection in untreated susceptible individuals. Carditis, the most serious manifestation of the disease, leads to severe and permanent valvular lesions, causing chronic rheumatic heart disease (RHD). We have been studying the mechanisms leading to pathological autoimmunity in RF/RHD for the last 15 years. Our studies allowed us a better understanding of the cellular and molecular pathogenesis of RHD, paving the way for the development of a safe vaccine for a post-infection autoimmune disease. We have focused on the search for protective T and B cell epitopes by testing 620 human blood samples against overlapping peptides spanning 99 residues of the C-terminal portion of the M protein, differing by one amino acid residue. We identified T and B cell epitopes with 22 and 25 amino acid residues, respectively. Although these epitopes were from different regions of the C-terminal portion of the M protein, they showed an identical core of 16 amino acid residues. Antibodies against the B cell epitope inhibited bacterial invasion/adhesion in vitro. Our results strongly indicated that the selected T and B cell epitopes could potentially be protective against S. pyogenes.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (00/14549-4)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (301775/83-4)
This publication has 10 references indexed in Scilit:
- The global burden of group A streptococcal diseasesThe Lancet Infectious Diseases, 2005
- HLA, CTLA-4 and PTPN22: the shared genetic master-key to autoimmunity?Expert Reviews in Molecular Medicine, 2005
- Prospects for a Group A Streptococcal Vaccine: Rationale, Feasibility, and Obstacles--Report of a National Institute of Allergy and Infectious Diseases WorkshopClinical Infectious Diseases, 2005
- Clinical and Microbiological Responses of Volunteers to Combined Intranasal and Oral Inoculation with a Streptococcus gordonii Carrier Strain Intended for Future Use as a Group A Streptococcus VaccineInfection and Immunity, 2005
- Group A Streptococcal Pharyngitis Serotype Surveillance in North America, 2000–2002Clinical Infectious Diseases, 2004
- Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcusInternational Immunology, 1997
- Treatment of Acute Streptococcal Pharyngitis and Prevention of Rheumatic Fever: A Statement for Health ProfessionalsPediatrics, 1995
- Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococciInfection and Immunity, 1988
- Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A.The Journal of Experimental Medicine, 1988